Cigna (CI) came out with quarterly earnings of $6.64 per share, missing the Zacks Consensus Estimate of $7.83 per share. This compares to earnings of $6.79 per share a year ago.
Cigna forecast annual profit below Wall Street expectations on Thursday and missed estimates for the fourth quarter, hurt by higher medical costs for a type of employer-sponsored healthcare plan.
The Cigna Group Thursday reported more than $3.4 billion in 2024 net income including $1.4 billion in the fourth quarter as the health insurer worked to overcome rising medical expenses in its employer plans.
Cigna's unit Evernorth Health said on Wednesday it will take several steps to help lower out-of-pocket cost of prescription drugs for patients at its pharmacy stores.
CI's fourth-quarter results are likely to have benefited from growing premiums and pharmacy revenues.
Cigna's current valuation presents a compelling opportunity, trading at a forward PE of 9.9, significantly below its historical average of 12.0x. The company carries diversified revenue streams and consistent earnings growth, with Healthcare and Evernorth divisions driving strong performance and a 13% EPS CAGR over 10 years. Management targets 10-14% long-term annual EPS growth, supported by increased biosimilar adoption, behavioral health services growth, and aggressive share buybacks.
As the calendar turns to 2025, the leading Wall Street firms are releasing their top stock picks for the new year.
The U.S. economy added 256,000 jobs last month, far exceeding expectations, which suggests a strong economy but reduces the likelihood of further Fed rate cuts. Rising long-term rates increase borrowing costs and competition for stocks, negatively impacting rate-sensitive sectors like utilities, real estate, and consumer staples. Despite a challenging market environment, equities still offer value, particularly in high-quality blue-chip stocks.
Employers are increasingly requiring workers on GLP-1 medications to enroll in nutrition and lifestyle coaching programs. Startup Virta Health saw 60% revenue growth last year, topping $100 million, driven by demand for its employer weight loss management program.
Despite market challenges, CI's strong fundamentals and growth drivers make it worth holding for long-term investors looking to capitalize on future recovery opportunities.
The health insurance industry has received a lot of backlash over its managed care practices that bog down providers with pre-authorizations and rampant medical claim denials. The rise in medical benefits ratios (MBRs) driven by Medicare Advantage plans have squeezed margins for major health insurance providers like Humana Inc. NYSE: HUM, UnitedHealth Group Inc. NYSE: UNH, and CVS Health Co. NYSE: CVS.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.